

Rituximab treatment and imaging of therapy resistant lung inflammation

Drs. H. Adams, MD, MSc, medisch specialist

Projectgroep:

Prof.dr. J.C. Grutters
Mevr. Dr. R.G. M. Keijsers
Dr. E.M.W. van de Garde
Mevr. Dr. Y.A. de Man
Mevr. Dr. A.M.E. Claessen
Prof.dr. D.H. Biesma

Clinical Physicists

Dr. J.B.A Habraken
Dr. R. Rooij

Acknowledgement:

Dr. F. Brijker (Diakonessenhuis)
Mevr. Dr. C. van Moorsel


Grants, sponsors:

ZonMw Goed Gebruik Geneesmiddelen (GGG)
Antonius Onderzoeksfonds
Longfibrose belangenvereniging
Longfonds


Zr-89-Rituximab

Prof. Dr. G. van Dongen
Cyclotron VU

Zeldzame onstekings longziekten (vorming van littekens)



UIP




NSIP



Normaal

In de praktijk




- 1e en/of 2e lijn therapie werkt niet
- Levensbedreigend (overlijden indien onbehandeld)

Zeldzame longziekten

Innovatie mogelijk?


Nieuwe medicijnen: anti-lichaam therapie



Anti-lichaam therapie

Nadelen?

Zeer kostbaar, werkt in ca. 30% niet



Werkt anti-lichaam therapie?


Vaak bloed prikken, longfunctie, afwachten



Ideaal: vooraf zien of therapie werkt:




Vooraf zien of therapie werkt?




Doel van het onderzoek

Werkt anti-lichaam therapie goed?

***Kan een immuno PET scan voorspellen
wanneer therapie niet gaat werken?***



Immuno PET scan bij reuma



Target to background ratio of PET positive joints




Fig. 3 Target-to-background ratios of positron emission tomography (PET)-positive joints in relation to clinical response, in those patients who had at least one PET-positive joint on visual interpretation

Doel van het onderzoek voor Immuno PET

Stap 1: is het veilig?

Stap 2: komt het in de longen aan?

Stap 3: correleert het beeld met de response?

Stap 4: Optimalisatie...



Grants

10 january 2013 begin writing grant

18 juni 2013 ZonMW grant

18 december 2013 Antonius onderzoeksfonds

De weg naar immune PET

- 2 centers who produce Zr89 (VUMC & UMCG)
- 1 reuma study at the time in NL (also internationally only 1)
- METC 22-07-2014 approval
- Start inclusion 1-08-2014
- Licensing pharmacy and lab 1-11-2014


Referrals

- Inclusions from all of the Netherlands
- Zeldzame ziekte

Start november 2014 - 2017

RESULTS:


TBR of immune PET controls vs IMID-IP




Casus: FDG vs immuno PET: # 010

Good responder




A



B





C



fNSIP scleroderma


Casus: FDG vs immuno PET: #006




Moderate responder
UIP RA

Casus: FDG vs immuno PET


A



B




C




Partial responder
UIP ASS


FVC 86,7% response



DLCO 73,4% response



Response and relative change in FVC after RTX 6 months




13.3%


26.7%

60.0%


Response and relative change in DLCO after RTX 6 months



TBR of immuno PET lungs (SUVmax) FVC



TBR of immuno PET lungs (SUVmax) DLCO



Doel van het onderzoek voor Immuno PET

Stap 1: is het veilig? ✓

Stap 2: komt het in de longen aan? ✓

Stap 3: correleert het beeld met de response? ✓

Stap 4: Optimalisatie... ✗



Signaal ruis verhouding
Kosten, tijd op afdeling

Gevoeligere apparatuur
Dosis escalatie studies

Hartelijk dank voor uw aandacht!



Dank aan:

